Bbva Compass Bancshares Inc. Sells 2,005 Shares of Mednax, Inc (MD)

Bbva Compass Bancshares Inc. decreased its position in shares of Mednax, Inc (NYSE:MD) by 10.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 17,254 shares of the company’s stock after selling 2,005 shares during the quarter. Bbva Compass Bancshares Inc.’s holdings in Mednax were worth $744,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in MD. OppenheimerFunds Inc. boosted its position in shares of Mednax by 14.5% during the 1st quarter. OppenheimerFunds Inc. now owns 11,379 shares of the company’s stock valued at $789,000 after acquiring an additional 1,439 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Mednax by 0.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 9,099 shares of the company’s stock valued at $632,000 after acquiring an additional 47 shares during the last quarter. Morgan Stanley boosted its position in shares of Mednax by 78.3% during the 1st quarter. Morgan Stanley now owns 361,509 shares of the company’s stock valued at $25,082,000 after acquiring an additional 158,720 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its position in shares of Mednax by 7.5% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 279,799 shares of the company’s stock valued at $19,413,000 after acquiring an additional 19,592 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. boosted its position in shares of Mednax by 1.3% during the 1st quarter. Nomura Asset Management Co. Ltd. now owns 11,300 shares of the company’s stock valued at $784,000 after acquiring an additional 140 shares during the last quarter. 99.97% of the stock is currently owned by hedge funds and other institutional investors.

In other Mednax news, insider John C. Pepia sold 3,000 shares of the business’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $42.85, for a total transaction of $128,550.00. Following the sale, the insider now directly owns 35,569 shares in the company, valued at $1,524,131.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Cesar L. Alvarez sold 10,668 shares of the business’s stock in a transaction dated Friday, November 3rd. The stock was sold at an average price of $42.59, for a total transaction of $454,350.12. Following the sale, the director now owns 44,215 shares in the company, valued at $1,883,116.85. The disclosure for this sale can be found here. 2.40% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: “Bbva Compass Bancshares Inc. Sells 2,005 Shares of Mednax, Inc (MD)” was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.com-unik.info/2017/11/05/bbva-compass-bancshares-inc-sells-2005-shares-of-mednax-inc-md.html.

Shares of Mednax, Inc (NYSE MD) opened at $43.37 on Friday. The stock has a market cap of $4,061.82, a PE ratio of 13.26, a P/E/G ratio of 1.41 and a beta of 0.32. Mednax, Inc has a fifty-two week low of $40.56 and a fifty-two week high of $72.13. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.37 and a quick ratio of 1.59.

Mednax (NYSE:MD) last issued its quarterly earnings data on Wednesday, November 1st. The company reported $0.87 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.87. The firm had revenue of $868.95 million for the quarter, compared to analyst estimates of $864.78 million. Mednax had a net margin of 7.76% and a return on equity of 10.80%. Mednax’s revenue was up 4.9% on a year-over-year basis. During the same period in the previous year, the firm earned $1.09 EPS. equities analysts predict that Mednax, Inc will post 3.08 earnings per share for the current year.

Several research analysts have recently weighed in on the stock. Citigroup Inc. lowered their price target on shares of Mednax from $52.00 to $47.00 and set a “neutral” rating on the stock in a research report on Friday. Robert W. Baird boosted their price target on shares of Mednax from $47.00 to $48.00 and gave the company a “neutral” rating in a research report on Friday. Jefferies Group LLC reissued a “hold” rating and set a $44.00 price target on shares of Mednax in a research report on Friday. KeyCorp set a $51.00 price target on shares of Mednax and gave the company a “buy” rating in a research report on Wednesday. Finally, BMO Capital Markets assumed coverage on shares of Mednax in a research report on Monday, October 16th. They set a “market perform” rating and a $46.00 price target on the stock. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and two have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $54.50.

Mednax Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mednax, Inc (NYSE:MD).

Institutional Ownership by Quarter for Mednax (NYSE:MD)

What are top analysts saying about Mednax Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mednax Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit